Delta 9 tetrahydrocannabinol - PhytoPain Pharma

Drug Profile

Delta 9 tetrahydrocannabinol - PhytoPain Pharma

Alternative Names: Cannabidiol; Delta-9-tetrahydrocannibinol; PPP-001; Smokeable marijuana

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator PhytoPain Pharma
  • Class Analgesics; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neuropathic pain

Most Recent Events

  • 07 Jun 2017 PhytoPain Pharma and Santé Cannabis plans a phase III trial for Neuropathic Pain in fourth quarter of 2017 or in the first quarter 2018
  • 29 May 2017 PhytoPain Pharma plans Expanded Access Programme for Neuropathic pain in USA and Canada (Tetra Bio-Pharma website, May 2017)
  • 29 May 2017 PhytoPain Pharma announces intention to file for marketing approval with the Health Canada and US FDA for Neuropathic pain in early 2019 (Tetra Bio-Pharma website, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top